GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Oncology/Underwater Endoscopy for Colorectal Neoplasia : Frontline Gastroenterol | Jun 2026
43

Underwater Endoscopy for Colorectal Neoplasia : Frontline Gastroenterol | Jun 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated June 1, 2026

Introduction:

Water-assisted and immersion-based endoscopic techniques are increasingly transforming the diagnosis and treatment of colorectal neoplasia. Unlike conventional gas insufflation, these approaches replace luminal gas with water or saline, creating a different optical and mechanical environment within the gastrointestinal tract. This can improve lesion visualisation, facilitate endoscopic resection, and enhance patient comfort. Over the past decade, underwater techniques have evolved from simple insertion methods to advanced therapeutic platforms for complex colorectal lesions.

Problem Statement:

Despite major advances in colonoscopy and endoscopic resection, challenges remain in optimizing adenoma detection, improving procedural comfort, and achieving safe and effective removal of complex colorectal neoplasms. Conventional techniques may be limited by suboptimal visualisation, difficult lesion access, and procedural complexity. There is growing interest in whether underwater and immersion-assisted approaches can overcome these limitations and improve both diagnostic and therapeutic outcomes.

Summary:

This review highlights the expanding role of underwater endoscopy across the spectrum of colorectal neoplasia management. Water-aided colonoscopy (WAC) has been associated with improved patient tolerance, enhanced bowel cleanliness, better adenoma detection, and smoother procedural performance. Underwater endoscopic mucosal resection (U-EMR) has emerged as an effective technique for colorectal lesion removal, offering efficient resection with favorable outcomes and reduced recurrence in selected cases. More recently, saline-immersion strategies such as the Saline-Immersion/Irrigation Technique (SITE) have been incorporated into endoscopic submucosal dissection (ESD). By creating a fluid-filled operative field, SITE may enhance visualisation, provide buoyancy-assisted tissue traction, improve electrosurgical performance, and potentially reduce thermal injury. Early experience suggests that SITE-ESD may simplify technically demanding dissections and improve procedural safety. Collectively, underwater endoscopy is evolving into a comprehensive platform for colorectal neoplasia management, with growing evidence supporting its integration into routine and advanced endoscopic practice. Further standardization and prospective studies will help define its optimal role in modern therapeutic endoscopy.

Related Q&A

44

GLP-1 Agonists with TNT in Rectal Cancer: Metabolic Optimization Meets Oncology: British Journal of Surgery | June 2026

This review explores a novel concept: whether GLP-1 receptor agonists can improve outcomes when combined with total neoadjuvant therapy in locally advanced rectal cancer. Total neoadjuvant therapy is...

45

KRAS + MTAP Loss Defines a Poor-Risk Pancreatic Cancer Subgroup: Clinical Cancer Research | June 2026

This study highlights the importance of comprehensive genomic profiling in pancreatic adenocarcinoma, not only for identifying targetable alterations but also for defining biologically distinct prognostic subgroups. The analysis...

46

BREAKWATER Cohort 3: New First-Line Standard for BRAF V600E Metastatic Colorectal Cancer: Annals of Oncology | May 2026

BRAF V600E-mutant metastatic colorectal cancer represents one of the most aggressive molecular subtypes of colorectal cancer, accounting for approximately 8%–12% of cases and historically associated with poor outcomes....

47

EOCRC Treatment Delays: Language Barriers Are a Modifiable Risk Factor: JAMA Oncology | June 2026

Early age–onset colorectal cancer is increasing globally and is now a major public health concern, especially because many patients present before routine screening age. This population-based Texas Cancer...

48

PRISM Study: Real-World Outcomes of First-Line Systemic Therapy for Unresectable HCC: Liver Cancer | May 2026

PRISM is one of the largest prospective real-world studies evaluating systemic therapy for unresectable hepatocellular carcinoma in routine clinical practice across Japan. This analysis reports outcomes from the...

49

DUPAN-2 Enables Biomarker Monitoring in CA19-9 Nonexpressors : JAMA Surg | Jun 2026

Introduction: Introduction: Carbohydrate antigen 19-9 (CA19-9) is the most widely used serum biomarker in pancreatic ductal adenocarcinoma (PDAC), guiding treatment response assessment, prognostication, and postoperative surveillance. However, approximately...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer